The European Interferon beta Pregnancy Registry


 

The European Interferon beta Pregnancy Registry represents the largest prospective cohort providing safety data on women with MS of childbearing age who have been exposed to any of the interferon beta therapies [1]. The registry included both spontaneous and solicited reports of pregnancies from patient support programs and Marketing Authorization Holder pharmacovigilance databases from 2009-2017.

 

 

Alt tag

  

 

Alt tag

The vast majority of known pregnancy outcomes of patients with exposure to interferon beta were live births without congenital anomalies [1]

 

 

Rates of spontaneous abortions and live births with congenital anomalies were consistent with those reported for the general population (spontaneous abortions: 10.7% vs 10-21%2; congenital anomalies: 2.1% vs 2.1-4.1% [3,4]) [1].

“Results from the registry showed no evidence that interferon beta exposure before conception and/or during early pregnancy increased the rate of congenital anomalies or spontaneous abortions, thus indicating that treatment with interferon beta may be continued until pregnancy is confirmed [1].”

 

 

References

Alt tag